Monaleze Saini, MD
Family Medicine · Custer, SDNPI 1053793307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $544 and has fallen 78.6% since, to $116 in 2025. Among family medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$347
- Amgen$236
- AstraZeneca$200
- Bayer$180
- Lilly USA, LLC$128
- Sanofi-aventis U.S. LLC$125
- plus $661 from 9 others
What the payments were for
- Food & beverage$1,878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $347 |
| Amgen | 15 | $236 |
| AstraZeneca | 5 | $200 |
| Bayer | 5 | $180 |
| Lilly USA, LLC | 9 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Boehringer Ingelheim | 9 | $121 |
| E.r. Squibb & Sons, L.L.C. | 8 | $119 |
| AbbVie | 3 | $88 |
| GSK | 6 | $83 |
| Pfizer | 4 | $66 |
| Exact Sciences | 4 | $59 |
| Novartis | 4 | $55 |
| Merck | 3 | $45 |
| Grifols USA, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$125
- Kerendia$125
- FASENRA$116
How this compares
$1,878 in reported general payments places this provider in the 90th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $97,227 |
| EliquisApixaban | 115 | $85,358 |
| JardianceEmpagliflozin | 54 | $56,853 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $54,576 |
| FarxigaDapagliflozin Propanediol | 22 | $36,292 |
| TrulicityDulaglutide | 22 | $31,141 |
| XareltoRivaroxaban | 17 | $27,053 |
| RybelsusSemaglutide | 15 | $22,979 |
| BelsomraSuvorexant | 11 | $14,394 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,866 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,251 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,433 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,354 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $347 | $120,20685 claims |
| PfizerEliquis | $66 | $85,358115 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $121 | $64,28669 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $83 | $62,66870 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $200 | $49,15842 claims |
| Lilly USA, LLCTrulicity | $128 | $31,14122 claims |
| MerckBelsomra | $45 | $14,39411 claims |
| AbbVieSynthroid, Armour Thyroid | $88 | $3,69496 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Custer
- Terry GraberCuster$6K
- Brandyn TarapCuster$3K
- Joy FalkenburgCuster$3K
- Lisa BrownCuster$2K
- Louise HalbleibCuster$1K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.